Home > Insider Trading > Filing (0001209191-20-052246)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382101	Sutro Biopharma Inc.	STRO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1326592	Trevor Hallam	C/O Sutro Biopharma, Inc. 310 Utah Avenue, Suite 150 South San Francisco CA 94080	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-25	11,019	$0.00	27,809	No	4	M	Direct
Common Stock	Disposition	2020-09-25	3,810	$10.30	23,999	No	4	F	Direct
Common Stock	Acquisiton	2020-09-25	6,887	$0.00	30,886	No	4	M	Direct
Common Stock	Disposition	2020-09-25	2,381	$10.30	28,505	No	4	F	Direct
Common Stock	Disposition	2020-09-28	975	$10.26	27,530	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit (RSU)	Disposition	2020-09-25	11,019	$0.00	11,019	$0.00
Common Stock	Restricted Stock Unit (RSU)	Disposition	2020-09-25	6,887	$0.00	6,887	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,019		2021-09-26	No	4	M	Direct
0		2020-09-26	No	4	M	Direct

Footnotes

Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.
The RSUs vest as to 1/2 of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.